References
- CHANG, T. K. H., WEBER, G. F., CRESPI, C. L. and WAXMAN, D. J., 1993, Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research, 53, 5629–5637.
- FITZSIIVIMONS, M. E. and COLLINS, J. M., 1997, Selective biotransforrnation of the human immuno-deficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4-potential contribution to high first-pass metabolism. Drug Metabolism and Disposition, 25, 256–266.
- GOREN, M. P., WRIGHT, R. K., PRATT, C. B. and PELL, P. E., 1986, Dechloroethylation of ifosfamide and neurotoxicity. Lancet, ii, 1219–1220.
- Hyr, K. F., TEE, L. B. G., REEVES, P. T. and MINCHIN, R. F., 1990, Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacology Therapeutics, 46, 67–93.
- KRISHNA, D. R. and KLOTZ, U., 1994, Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinetics, 26, 144–160.
- KAUSER, G. P., KORST, A., BEUNEN, J. H., BULT, A. and UNDERBERG, W. J. M., 1993, The analysis of ifosfamide and its metabolite. Anticancer Research, 13, 1311–1324.
- KAMINSKY, L. and FASCO, M. J., 1992, Small intestinal cytochromes P450. Critical Review of Toxicology, 21, 407–422.
- NIEH, Y. C., 1994, Stereoselective disposition and bioavailability study of ifosfamide in the rat following oral administration. Master thesis, The Ohio State University.
- RUZICKA, J. A. and RUENITZ, P. C., 1992, Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat. Drug Metabolism and Disposition, 20, 770–772.
- WAGNER, T., 1994, Ifosfamide clinical pharmacokinetics. Clinical Pharmacokinetks, 26, 439-456. WAINER, I. W., DUCHARME, J., GRANVIL, C. P., TRUDEAN, M. and LEYLAND -JONES, B., 1994, Ifosfamide stereoselective dechloroethylation and neurotoxicity. Lancet, 343, 982–983.
- WALKER, D., FLINOIS, J. P., MONKMAN, S. C., BELOC C., BODDY, A. V., CHOLERTON S., DALY, A. K., LIND, M. J., PEARSON, A. D. J., BEAUNE, P. H. and IDLE, J. R., 1994, Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochemical Pharmacology, 47, 1157–1163.
- WANG, J. H. and CHAN, K. K., 1995a, Identification of new metabolites of ifosfamide in rat urine using ion cluster technique. Journal of Mass Spectrometry, 30, 675–683.
- WANG, J. H. and CHAN, K. K., 1995b, Analysis of ifosfamide, 4-hydroxyifosfamide, N2-dechloroethylifosfamide, N3-dechloroethylifosfamide, and iphosphamide mustard in plasma by gas chromatography-mass spectrometry. Journal of Chromatography, 674, 205–217.
- WEBER, G. F. and WAXMAN, D. J., 1993, Activation of the anti-cancer drug ifosfamide by rat liver microsomal P450 enzymes. Biochemical Pharmacology, 45, 1685–1694.
- Yu, L. and WAXMAN, D. J., 1996, Role of cytochrome P450 in oxazaphosphorine metabolism, deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochrome P450. Drug Metabolism and Disposition, 24, 1254–1262.
- ZHANG, Q. Y., WIKOFF, J., DUNBAR, D. and KAMINSKY, L., 1996, Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug Metabolism and Disposition, 24, 322–328.